Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2010-08-18 Major Shareholding Noti…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2010
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific instrument (AK B SE0000273294) held by Länsförsäkringar Fondförvaltning AB in Medivir Aktiebolag. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (e.g., dropping from 11.95% to 9.75%). This content directly corresponds to the definition of a Major Shareholding Notification.
2010-08-18 English
Declaration of Voting Results & Voting Rights Announcements 2010
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short press release dated July 30, 2010, announcing a change in the total number of shares and votes due to the exercise of employee stock options. This directly relates to a change in the company's capital structure (share count). The most specific category for changes in share capital or new share issues is 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the content is specific enough to warrant SHA over the general RPA or RNS fallback.
2010-07-30 English
Share Issue/Capital Change 2010
Share Issue/Capital Change Classification · 99% confidence The document is a short press release dated July 30, 2010, announcing a change in the total number of shares and votes in the company due to the exercise of employee stock options. This directly relates to a change in the capital structure or share count. The most specific category for changes in share count or capital structure is 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the content itself is the core information (the new share count), not just an announcement that a report is available. Therefore, SHA is the best fit.
2010-07-30 Swedish
Earnings Release 2010
Earnings Release Classification · 99% confidence The document is titled "Press Release 12 July 2010" and announces "Phase 2b 24-week Interim Results of TMC435 in Treatment-naïve Patients Chronically Infected with Genotype-1 Hepatitis C Virus." It details clinical trial efficacy and safety data, concluding with an invitation to a teleconference to discuss these results. This format—a press release announcing key clinical trial results (efficacy, safety, interim data) for a drug candidate—is characteristic of an Earnings Release (ER) or a general announcement related to financial/operational performance, but since it is specifically about clinical trial results and not quarterly financials, it fits best under the general category for operational updates or regulatory announcements. Given the options, it is a primary announcement of operational/clinical performance data, which often accompanies or precedes a formal Earnings Release, but since it is a standalone press release detailing interim results, it aligns most closely with the function of an Earnings Release (ER) which provides key highlights of recent performance/developments, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, the content is a direct announcement of key operational/clinical milestones, making ER the closest fit among the performance-related codes, as it is the initial release of period-specific performance data (interim trial results). It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). I will classify it as an Earnings Release (ER) as it serves as the initial public disclosure of significant operational performance metrics. FY 2010
2010-07-12 English
Earnings Release 2010
Earnings Release Classification · 99% confidence The document is titled "Pressmeddelande" (Press Release) and dated July 12, 2010. It announces interim results from a Phase 2b clinical trial (PILLAR study) for a drug candidate (TMC435) treating Hepatitis C. The content focuses on clinical efficacy, safety data, and future plans for clinical trials. This structure—a formal announcement of key results, often preceding a full report or presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release detailing specific, time-sensitive financial/operational results (clinical trial outcomes), it fits best under 'Earnings Release' (ER) as it serves as the initial public disclosure of performance metrics, even if the performance is clinical rather than purely financial revenue. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). It is a direct announcement of results. FY 2010
2010-07-12 Swedish
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January – 30 June 2010. It contains comprehensive financial statements, including income statements, cash flow analysis, and detailed management commentary on business performance, R&D projects, and financial position. It is not a mere announcement (RPA) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H2 2010
2010-07-08 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.